

---

# Near Infra-Red Fluorescence

Initiative Type

Technology

Status

Deliver

Added

01 September 2017

Last updated

27 September 2018

URL

<https://cnxp3cuvtvrn68yjaibaht5ywrxspj7m.clinicalexcclence.qld.gov.au/improvement-exchange/fluorescence>

## Summary

Real-time intraoperative near-infrared fluorescence (NIRF) imaging is a technique used for sentinel lymph node (SLN) detection. By using a NIR fluorescent dye such as indocyanin green (ICG), and a sensitive fluorescence camera system, SLN's can be located intra-operatively for examination. Although this technology has been employed for breast, skin and colorectal cancers, in this instance

---

it will be investigated for endometrial cancer. Where SLN's are positive for metastases, the patient will undergo adjuvant radiation and chemotherapy but with reduced morbidity as a full lymph node dissection has not been performed. If the SLN is negative, patients can be spared further therapy.

### Key dates

Jan 2018

Dec 2018

### Implementation sites

Royal Brisbane and Women's Hospital

### Partnerships

Healthcare Improvement Unit

## Key Contacts

Jacqui Thomson

1037

[paul.blee@hiu](mailto:paul.blee@hiu)

Manager, Healthcare Evaluation and Assessment of Technology

Healthcare Improvement Unit

(07) 3328 9283

secretariat\_hta@health.qld.gov.au

---

## Aim

Provides an opportunity to pilot and evaluate new technologies within 'real world' clinical settings in the Queensland context.

## Benefits

The potential benefits of this technology includes:

- NIRF with ICG will assist in mapping the SNL location.
- NIRF with ICG should reduce the rate of adjuvant radiation and/or chemotherapy given to patients.
- NIRF with ICG is feasible and safe and should replace full lymph node dissection.
- NIRF with ICG will reduce the number of full pelvic lymphadenectomies required.
- NIRF with ICG should reduce surgical morbidity for the patient and also reduce morbidity associated with lymphoedema.
- NIRF with ICG should be tolerated by the patient with very low risk of side effects.

## Background

This technology was funded through the New Technology Funding and Evaluation Program (NTFEP). The NTFEP funds the introduction and evaluation of new technologies that:

- Are safe and effective
- Provide better health outcomes
- Provide value for money
- Provide greater access to care.

The evaluation findings will inform recommendations regarding the future use and/or investment of the technology within Queensland.

## Evaluation and Results

This technology is currently under evaluation and results will be published on completion.

---

## Resources

[Technology evaluation summary](#)

PDF saved 24/11/2024